Compare Incyte Corporation (INCY) vs Star Bulk Carriers Corp (SBLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Star Bulk Carriers Corp — how do they compare? Incyte Corporation trades at $115.71 (market cap $23.11B), while Star Bulk Carriers Corp trades at $26 (market cap $2.91B). The key difference: Incyte Corporation is far larger — about 7.9× Star Bulk Carriers Corp's market cap, and Star Bulk Carriers Corp pays a 3.95% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | SBLK | |
|---|---|---|
Market Cap | $23.11B | $2.91B |
Sector | Health | Industrials |
52-Week High | $118.52 | $28.21 |
52-Week Low | $67.38 | $16.79 |
Enterprise Value | $19.13B | $3.61B |
Dividend Yield | — | 3.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Star Bulk Carriers (SBLK) trades at $26.09, up 4.78% in the last session. Technical indicators are bearish, but fundamentals show strength with a P/E of 19.92 and net income margin of 13.01%. Recent earnings beat expectations in Q4 2025 and Q1 2026, with Q2 2026 EPS expected at $0.96. The company maintains a healthy balance sheet and pays dividends, including a recent $0.50 per share distribution.
Outlook is cautiously optimistic due to strong dry bulk rates and fleet modernization driving cash flow. Risks include shipping rate volatility and macroeconomic pressures. Analyst consensus is bullish with 58.34% buy ratings, but technical weakness suggests near-term caution. The stock offers value with a 10%+ dividend yield potential if rates sustain.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Star Bulk Carriers Corp
Star Bulk Carriers Corp. is a global shipping company specializing in the seaborne transportation of dry bulk commodities. The company owns and operates a large fleet of bulk carriers, primarily transporting major commodities such as iron ore, coal, and grain. SBLK focuses on the Capesize, Post Panamax, and Kamsarmax vessel segments, providing critical logistical services to commodity producers and consumers worldwide.
Read more on SBLK →
